







4. Rees DC, Cox Clegg JB. World distribution of faktor V Leiden. *Lancet* 1995; 346: 1133-1134.
5. Gurgey A, Mesci L. The prevalence of faktor V Leiden (1691 G-A) mutation in Turkey. *Türk J Pediatr* 1997; 39: 313-315.
6. Ozbek U, Tangun Y. Frequency of faktor V Leiden (Arg506Gln) in Turkey. *Br J Haematol* 1997; 97: 504-505.
7. Herrmann FH, Koelsing M, Schroder W, Altman R, Jimenez Bonilla R, Lopacik S, et al. Prevalence of faktor V Leiden mutation in various populations. *Genet Epidemiology* 1997; 14: 403-411.
8. Pečeniuk NM, March NA, Walsh NA, Dale JL. Use of first nucleotide change technology to determine the frequency of faktor V Leiden in a population of Australian blood donors. *Blood Coagulation Fibrinolysis* 1997; 8: 491-495.
9. Garcia-Gala JM, Alvarez V, Pinto CR, Soto I, Urgelles MF, Menender JM, et al. Faktor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based on the Spanish population. *Clin Genet* 1997; 52: 206-210.
10. Ridker PM, Miletič JP, Hennekens CH, Buring JE. Ethnic distribution of faktor V Leiden in 4047 men and women. *JAMA* 1997; 277: 1305-1307.
11. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl genotype (Gln 506) of coagulation faktor V are rare in Japanese population. *Thromb Haemost* 1995; 74: 996-1002.
12. de Maat MPM, Klufft C, Jespersen J, Gram J. World distribution of faktor V Leiden mutation. *Lancet* 1996; 347: 58.
13. Fujimura H, Kambayashi J, Monden M, Kato H, Miyata T. Coagulation faktor V Leiden mutation may have a racial background. *Thromb Haemost* 1996; 74: 1381-1382.
14. Dahlback B. Resistance to activated protein C caused by faktor V R506Q mutation is a common risk faktor for venous thrombosis. *Thromb Haemost* 1997; 78: 483-488.
15. Gurgey A, Hiçsönmez G, Parlak H, Balta G, Celiker A. PG20210A mutation in Turkish Patients with Thrombosis. *Am J Hematology* 1998; 59: 179-180.
16. Akar N, Misirlioglu M, Akar E, Avcu F, Yalcin A, Sozuoz A. Prothrombin gene 20210 G-A mutation in the Turkish population. *Am J Hematol* 1998; 58: 249.
17. Lay MJ, Wittwer CT. Real-time fluorescence genotyping of faktor V Leiden during rapid-cycle PCR. *Clinical Chemistry* 1997; 43: 2262-2267.
18. Nauch M, Marz W, Wieland H. Evaluation of the Roche Diagnostics Light Cycler-FVL Mutation Detection Kit and the Light Cycler-Prothrombin Mutation Detection Kit. *Clinical Biochemistry* 2000; 33: 213-216.
19. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of faktor V Leiden and prothrombin 20210A on the risk of venous thromboembolism—pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. *Thromb Haemost* 2001; 86: 809-816.
20. Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinielli P, et al. Lower birth-weight in neonates of mothers carrying faktor V G1691A and faktor II(A)(20210) mutations. *Haematologica* 2002; 87: 177-181.
21. Pipe SW, Schmaier AH, Nichols WC, Ginsburg D, Bozynski ME, Castle VP. Neonatal purpura fulminans in association with faktor V R506Q mutation. *J Pediatr* 1996; 128: 706-709.
22. Nowak-Gottl U, Binder M, Dubbers A, Kehrel B, Koch HG, Veltmann H, et al. Arg506 to Gln mutation in the faktor V gene causes poor fibrinolytic response in children after venous occlusion. *Thromb Haemost* 1997; 78: 1115-1118.
23. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Faktor V gene mutation is a risk faktor for cerebral venous thrombosis. *Thromb Haemost* 1996; 75: 393-394.
24. Zuber M, Toulon P, Marnet L, Mas JL. Faktor V Leiden mutation in cerebral venous thrombosis. *Stroke* 1996; 27: 1721-1723.
25. Hunt BJ. Activated protein C and retinal vein occlusion. *Br J Ophthalmol* 1996; 80: 194.
26. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. *Br J Ophthalmol* 1996; 80: 200-202.
27. Larsen TB, Norgaard-Pedersen B, Lundemose JB, Rudiger N, Gaustadnes M, Brandslund I. Sudden infant death syndrome, childhood thrombosis, and presence of genetic risk factors for thrombosis. *Thromb Res* 2000; 98: 233-239.
28. Mercuri E, Cowan F, Gupta G, Manning R, Laffan M, Rutherford M, Prothrombin disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. *Pediatrics* 2001; 107: 1400-1404.
29. Verity DH, Vaughan RW, Madanat W, Kondatis E, Zureikat H, Fayyad F, et al. Faktor V Leiden mutation is associated with ocular involvement in Behcet disease. *Am J Ophthalmol* 1999; 128: 352-356.
30. Akar N, Akar E, Dalgin G, Sözüoğlu A, Ömürlü K, Çin S. Frequency of Faktor V (1691 G-A) Mutation in Turkish Population. *Thromb Haemost* 1997; 78: 1527-1528.
31. Gul A, Ozbek U, Öztürk C, İnanç M, Koniçe M, Özcelik T. Coagulation Faktor V Gene Mutation increases the risk of venous thrombosis in Behçet's Disease. *Br J Rheumatology* 1996; 35: 1178-1180.
32. Irani-Hakime N, Tamim H, Kreidy R, Almawi YW. The prevalence of faktor V R506Q mutation in apparently healthy Lebanese. *Am J Hematology* 2000; 65: 45-49.
33. Schroder W, Koelsing M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for faktor V Leiden mutation in north-eastern German population. *Haemostasis* 1996; 26: 233-236.
34. Awidi A, Shannak M, Bseiso A, Kailani MA, Anshasi B, Omar N, et al. High prevalence of faktor V Leiden in healthy Jordanian Arabs. *Thromb Haemost* 1999; 81: 582-584.
35. Zoller B, Norlund L, Leksell H, Nilsson JE, von Schenck H, Rosen U, et al. High Prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. *Thromb Res* 1996; 83: 475-477.
36. Anchaisuksiri P, Pingsuthiwong S, Aryuchai K, Busabarathana M, Sura T, Atichartakam V, et al. Prevalence of the G1691A mutation of faktor V gene (faktor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. *Am J Hematol* 2000; 65: 119-122.
37. Gurgey A, Kudayarov DK, Tuncer M, Parlak H, Altay C. The faktor V Leiden and prothrombin G20210A mutations in Kirghiz population. *Thromb Haemost* 2000; 84: 356.
38. Togrul N, Rustamov R, Gurgey A, Altay S, Altay C. Prevalence of the prothrombin gene G20210A mutation in Azerbaijan. *Br J Haematol* 2000; 108: 887-888.
39. Antoniadis T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of faktor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. *Am J Hematol* 1999; 61: 263-267.
40. Hepner M, Roldan A, Pieroni G, Fronthof JP, Serviddio RM, Torres AF, et al. Faktor V Leiden mutation in the Argentinean population. *Thromb Haemost* 1999; 81: 989.
41. Balogh I, Poka R, Pflieger G, Dekany M, Boda Z, Muszbek L. High prevalence of faktor V Leiden mutation and 20210A prothrombin variant in Hungary. *Thromb Haemost* 1999; 81: 660-661.
42. Adamczuk Y, Iglesias Varela ML, Forastiero R, Martinuzzo M, Cerrato G, Pombo G, et al. Faktor V Leiden and prothrombin G20210A variant are risk factors for venous thromboembolism in the Argentinean population. *Thromb Haemost* 2000; 83: 509-510.
43. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. *Thromb Haemost* 1998; 79: 706-708.
44. Ayyildiz O, Kalkanli S, Batun S, Aybak M, Iskigdan A, Tiftik N et al. Prothrombin G20210A gene mutation with light cyler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. *Heart Vessels* 2004 (in press).